Alcista
$245.24
Precio del escenario
$222.660
-1.648 (-0.74%)Al cierre
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.
Steris plc is a good buy right now due to its current price of $214.4, which is below analyst targets of $275 and $269, indicating significant upside potential. The company reported a strong Q1 2027 EPS of $2.59, exceeding expectations by $0.10, and a revenue growth of 7.9% year-over-year, showcasing solid market demand. However, the RSI is at 70.106, indicating it may be overbought, which is a risk to consider.
UBS
$275
2026-07-28
UBS
2026-07-28
Precio objetivo
$275
KeyBanc
$269
2026-05-13
KeyBanc
2026-05-13
Precio objetivo
$269
Morgan Stanley
—
2026-01-08
Morgan Stanley
2026-01-08
Precio objetivo
—
JPMorgan
—
2025-12-05
JPMorgan
2025-12-05
Precio objetivo
—
KeyBanc
$288
2025-07-22
KeyBanc
2025-07-22
Precio objetivo
$288
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

STERIS Acquires Xodus Medical for $2.1 Billion

STERIS plc Reports First Quarter Earnings Growth

Steris Reports Q1 2027 Earnings with Mixed Results

STERIS Reports Strong Q1 2027 Financial Results with Strategic Restructuring

STERIS Announces Quarterly Dividend Increase to $0.69
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
Steris plc is a good buy right now due to its current price of $214.4, which is below analyst targets of $275 and $269, indicating significant upside potential. The company reported a strong Q1 2027 EPS of $2.59, exceeding expectations by $0.10, and a revenue growth of 7.9% year-over-year, showcasing solid market demand. However, the RSI is at 70.106, indicating it may be overbought, which is a risk to consider.
8 analysts cover STE: 6 rate it Buy, 2 Hold and 0 Sell.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.